MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders. It is a prodrug of psilocin similarly to psilocybin, and hence acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. The animal pharmacodynamics and pharmacokinetics of MSP-1014 have been studied, demonstrating a shorter plasma half-life compared to psilocybin. The drug is under development by Mindset Pharma and Otsuka America Pharmaceutical. As of January 2024, it is in phase 2 clinical trials for major depressive disorder and is in the preclinical stage of development for anxiety disorders and other depressive disorders. The chemical structure of MSP-1014 does not yet seem to have been disclosed. However, Mindset Pharma patented psilocin derivatives and prodrugs in 2022.
See also Substituted tryptamine List of investigational hallucinogens and entactogens CT-4201, EB-002, and RE-109 (4-GO-DMT) Luvesilocin (4-GO-DiPT) MSP-2020
References